Page last updated: 2024-10-18

dalteparin and Spondylitis, Ankylosing

dalteparin has been researched along with Spondylitis, Ankylosing in 2 studies

Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)

Spondylitis, Ankylosing: A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.

Research Excerpts

ExcerptRelevanceReference
"A 61-year old patient with ankylosing spondylitis who was on secukinumab therapy for 5 months admitted with newly onset fever and gastrointestinal complaints."2.66Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. ( Coskun Benlidayi, I; Guzel, R; Kurtaran, B; Tirasci, E, 2020)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Coskun Benlidayi, I1
Kurtaran, B1
Tirasci, E1
Guzel, R1
Bodur, H1
Eser, F1
Konca, S1
Arikan, S1

Reviews

1 review available for dalteparin and Spondylitis, Ankylosing

ArticleYear
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
    Rheumatology international, 2020, Volume: 40, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antirheumatic Agents; Betacoronavirus; Coronaviru

2020

Other Studies

1 other study available for dalteparin and Spondylitis, Ankylosing

ArticleYear
Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis.
    Rheumatology international, 2009, Volume: 29, Issue:4

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Anticoagulants; Antirheumatic Agents; Enoxaparin;

2009